Thank you very much, Mr. Chair.
We are currently seeing an adjustment to what we have been observing for the past few days. Unfortunately, the government is trying to reduce accountability for its actions. We invested $300 million in a program that will be terminated in a few weeks, at the end of May, and now they are trying to remove the reference to the Treasury Board Secretariat from my motion. For those following our work, I would remind you that it is Treasury Board that signs the checks. It is Treasury Board that manages the money. We haven't received much explanation from our colleague, but he says that those who manage the money don't need to come here to explain to us the decisions they make regarding financial management.
So, it is appropriate to summon officials from the Treasury Board Secretariat. I repeat: If we want to discuss public funds, governance, contracts, termination, transition or even accountability, we need these people, because they are the ones making the decisions. If we want to understand the financial and administrative decisions surrounding PrescripTIon, representatives from the Treasury Board Secretariat are relevant witnesses. Removing this from the motion would weaken the committee's ability to track public funds and understand the decisions made by Treasury Board.
Next, my colleague proposes removing the two-week deadline. We've lost $300 million in public funds on an e‑prescription program, but it doesn't seem to be a priority for the government to understand what happened and learn from its mistakes. My colleague wants to remove the deadline, which would make it easy to postpone the motion indefinitely. We could put it off indefinitely, as they say.
Given the $300 million spent and the program's imminent end, the committee must act quickly, in my view. We have been asking questions—I think you are aware—for several weeks and trying to obtain information or documents from the government. Therefore, I believe it is reasonable to summon these witnesses within two weeks, or at the earliest opportunity, as stated in the motion I have tabled.
This is all the more reasonable and important given the mounting scandals involving the Liberal government. I would remind you of the scandals surrounding Phoenix, ArriveCAN, and Cúram, to which we can now add the one involving PrescripTIon. The government is sweeping this under the rug by telling us that it is not important to talk about it, that there is no need to shed light on it or conduct independent public inquiries, even if we fail to achieve the expected results.
Today, Ms. Ensor from Canada Health Infoway told us that, for the program to be viable, we needed to reach a 75% usage rate. Well, $300 million later, we've managed to reach 5%. The government does not think it is important to say that we really need to investigate this, get the facts, and ensure that it does not happen again. So, I urge my colleagues in the government to ensure sound management of public funds. That is, in fact, what the Prime Minister said he would do, even though that is not what he demonstrated in the last budget. He announced the largest deficit in Canadian history. However, as good stewards of public funds, we must investigate the PrescripTIon program.
There is a question I have been asking myself for a long time, and I would like to share it with my colleagues, the members of the committee, and the general public. The government must have known that there were problems somewhere. A review of the program's viability was conducted in 2023, yet investment in it continued, and it was only two years later, in 2025, that the decision was finally made to completely terminate the program.
I hope the government will explain the various decisions it made in this matter, because it is concerning. That is why I want its representatives to appear before us. Even after the decision was made to end the program, an additional $10 million was allocated.
I hope my colleagues will see reason regarding the motion, which is entirely reasonable and legitimate.